#4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: HU, *et al.*

Application Serial No.: 09/219,442 Art Unit: 1646

Filed: December 23, 1998 Examiner: Saoud, C.

For: Human Vascular Endothelial Growth Factor 2 Attorney Docket No.: PF112P2D1

3-5-99

RESPONSE TO NOTICE TO COMPLY AND REQUEST UNDER 37 C.F.R. §1.821(E)

Assistant Commissioner For Patents
Washington, D.C. 20231

Sir:

In response to the Communication and Notice to Comply (copy enclosed) dated February 1, 1999, applicants declare that the above-identified patent application is a divisional of application Serial No. 08/999,811, filed December 24, 1997. Accordingly, the sequence listing of the instant application is identical to the sequence content of the computer readable sequence listing previously filed in connection with application Serial No. 08/999,811.

In accordance with 37 C.F.R. § 1.821(e), applicants respectfully request that the Examiner use the computer readable form filed in connection with application Serial No. 08/999,811 as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant application. A paper copy of the Sequence Listing is included in the originally-filed specification of the instant application. Applicants hereby certify that the paper copy of the Sequence Listing filed in the instant application and the computer readable sequence listing previously filed in connection with application Serial No. 08/999,811 are the same and do not include new matter.

If there are any fees due in connection with the filing of this paper, please charge the fees to our deposit Account No. 08-3425. If a fee is required for an extension of time under 37 C.F.R. § 1.136 not accounted for above, such an extension is requested and the fee should also be charged to our Deposit Account.

Respectfully submitted,

Date: 2/24/99

Michele M. Wales (Reg. No. P-43,975)
Attorney for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, Maryland 20850
Telephone: 301-610-5772

MMW/lcc

Application No. 09/219,442

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

☐ 1. This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.

☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).

☑ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).

☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."

☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).

☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).

☐ 7.

Other: _____

Applicant must provide:

☑ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"

☐ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification

☑ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

For questions regarding compliance with these requirements, please contact:

For Rules Interpretation, call (703) 308-1123
For CRF submission help, call (703) 308-4212
For PatentIn software help, call (703) 557-0400

Please return a copy of this notice with your response.